Thomas Brechenmacher

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

J. Thaddeus Beck, Gabriel N. Hortobágyi, Mario Campone et al. · Breast Cancer Research and Treatment · 2013 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1

J.C. Kingswood, Sergiusz Jóźwiak, Michael Frost et al. · Nephrology Dialysis Transplantation · 2014 · 79 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Development of gatekeeping strategies in confirmatory clinical trials

Alex Dmitrienko, Brian A. Millen, Thomas Brechenmacher et al. · Biometrical Journal · 2011 · 44 citations

Public Health, Biostatistics, Diabetology +10

Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)

Robert J. Motzer, Anna Alyasova, D. Ye et al. · Annals of Oncology · 2015 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial

Sergiusz Jóźwiak, Katarzyna Kotulska, Noah Berkowitz et al. · The Journal of Pediatrics · 2016 · 35 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +7